Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.67 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.67 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27805088 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL27805090 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL16124664 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL360370 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL2578612 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL27890891 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL3506305 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL7797430 | 1.00 | P2RY10 (0.67) | P2RY10GPR34GPR174MAPTLMNA | |
| SCHEMBL7794681 | 0.91 | P2RY10 (0.71) | P2RY10GPR34GPR174DGKA | |
| SCHEMBL7794685 | 0.91 | P2RY10 (0.71) | P2RY10GPR34GPR174DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250134950-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2024227957-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2024-11-07 | — | — | WO | disclosed |
| US-12076366-B2 | Therapeutic vitamin D conjugates | EXTEND BIOSCIENCES, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| EP-3220961-B1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3220961-B1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11116816-B2 | Therapeutic vitamin d conjugates | EXTEND BIOSCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11116816-B2 | Therapeutic vitamin d conjugates | EXTEND BIOSCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210008153-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008153-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-6963807-B2 | Automated identification of peptides | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2005-11-08 | — | — | US | disclosed |
| US-20040253636-A1 | Method of protein analysis | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-12-16 | — | — | US | disclosed |
| EP-1430307-A2 | A METHOD OF PROTEIN ANALYSIS | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-06-23 | — | — | EP | disclosed |
| EP-1320754-A2 | DETECTION OF PEPTIDES | Oxford GlycoSciences (UK) Limited (GB) | 2003-06-25 | — | — | EP | disclosed |
| EP-1317765-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | Oxford GlycoSciences (UK) Limited (GB) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003027681-A2 | A METHOD OF PROTEIN ANALYSIS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-04-03 | — | — | WO | disclosed |
| US-20020102610-A1 | Automated identification of peptides | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
| US-20020055186-A1 | Detection of peptides | OXFORD GLYCOSCIENCES (UK) LTD. | 2002-05-09 | — | — | US | disclosed |
| WO-2002025287-A2 | DETECTION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002021139-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008153-A1 | THERAPEUTIC VITAMIN D CONJUGATES | VDR, CYP24A1, CYP2R1 | P2RY10 4692/4885GPR34 895/4885GPR174 185/4885 |
| US-12076366-B2 | Therapeutic vitamin D conjugates | VDR, CYP24A1, CYP2R1 | P2RY10 4692/4885GPR34 895/4885GPR174 185/4885 |
| US-20250134950-A1 | THERAPEUTIC VITAMIN D CONJUGATES | VDR, CYP24A1, CYP2R1 | P2RY10 4692/4885GPR34 895/4885GPR174 185/4885 |
| US-11116816-B2 | Therapeutic vitamin d conjugates | PTH1R, CYP24A1, VDR | P2RY10 2729/4885GPR34 882/4885GPR174 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.